Form 4: Arcus Biosciences Director Receives Equity Grant

Director Kathryn E. Falberg was granted 5,700 restricted stock units and 16,900 stock options by Arcus Biosciences.

Summary

• Director Kathryn E. Falberg received a grant of 5,700 restricted stock units (RSUs) on June 11, 2026.
• The director was also granted 16,900 stock options with an exercise price of $23.30.
• Both the RSUs and stock options are scheduled to vest in full on June 11, 2027, or at the next annual meeting of stockholders, whichever occurs first.
• The awards include provisions for full vesting in the event of a change in control of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of experienced board leadership through standard equity incentive structures.

Negatives

• Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.

Risks

• Market volatility affecting the value of equity grants.
• Potential for change in control scenarios to trigger accelerated vesting.

Future Outlook

The equity grants are subject to standard vesting schedules tied to time or the next annual meeting, aligning director incentives with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices among mid-cap biotechnology firms.
• Vesting periods of one year are typical for annual director equity refresh grants.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.

Next Steps

• Vesting of equity awards on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Equity Compensation, Director Compensation